MedTrace Logo

Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C

NCT00917358 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-12-20

No results posted yet for this study

Summary

Interferon-based monotherapy has been considered effective to treat acute hepatitis C in ordinary patients. However, the efficacy of this treatment has not been evaluated in prospective interventional studies for dialysis patients. The aim of the study is the evaluate the efficacy of peginterferon alfa-2a monotherapy for 24 weeks in this special clinical setting, and concomitantly evaluate retrospectively the dialysis patients with acute hepatitis C who did not receive intervention as the reference.

Conditions

  • Hepatitis C

Interventions

DRUG

Pegylated interferon alfa-2a

Pegylated interferon alfa-2a 135 ug/week for 24 weeks

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chen-Hua Liu, MD · National Taiwan University Hospital

  • Jia-Horng Kao, MD, PhD · National Taiwan University Hospital

  • Cheng-Chao Liang, MD · Far Eastern Memorial Hospital

  • Shih-Jer Hsu, MD · National Taiwan University Hospital, Yun-Lin Branch

  • Hung-Bin Tsai, MD · Buddhist Tzu Chi General Hospital

  • Peir-Haur Hung, MD · Chiayi Christian Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917358 on ClinicalTrials.gov